- Home
- LILAK vs PHVS Comparison
LILAK vs PHVS Comparison
Compare LILAK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | PHVS |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Bermuda | Switzerland |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LILAK | PHVS |
|---|---|---|
| Price | $7.77 | $25.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $8.20 | ★ $40.70 |
| AVG Volume (30 Days) | ★ 884.7K | 102.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.23 | $11.51 |
| 52 Week High | $9.13 | $29.80 |
Technical Indicators
Market Signals| Indicator | LILAK | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 41.76 |
| Support Level | $7.60 | $24.25 |
| Resistance Level | $8.44 | $26.11 |
| Average True Range (ATR) | 0.30 | 1.12 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 44.50 | 9.24 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.